Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia

NACompletedINTERVENTIONAL
Enrollment

333

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

September 27, 2020

Study Completion Date

September 27, 2020

Conditions
SARS VirusSARS-CoV-2COVID-19
Interventions
OTHER

Convalescent SARS COVID-19 plasma

Convalescent SARS COVID-19 plasma from a pool of 10 donor plasma. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.

OTHER

Placebo

Single infusion of saline solution, in addition to standard care. The calculation of the volume to be transfused will be from 10 to 15 ml / kg adjusting the volume to the body weight of each patient, at a suggested infusion rate of 5 to 10 ml / kg / h with an intravenous infusion pump. The infusion rate will be adjusted according to the clinical stability of the patient according to the treating physician.

Trial Locations (1)

1181

Hospital Italiano de Buenos Aires, Ciudad Autonoma de Buenos Aire

All Listed Sponsors
lead

Hospital Italiano de Buenos Aires

OTHER

NCT04383535 - Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia | Biotech Hunter | Biotech Hunter